News

An investigational drug has shown positive activity against metastatic uveal melanoma in a phase 1 study.

In this Q&A, Vance Thompson, MD, clears up myths about dry eye and LASIK wearing off, and explains how better screening and technology are making the procedure more precise for younger patients.

Findings highlight the need for routine bilateral endothelial assessment in herpetic eye disease

Choosing the right IOL for patients seeking spectacle independence is increasingly complex as novel optical designs enter the field. This comparative case report explores how a proven diffractive trifocal IOL (AT LISA tri 839MP) performs against a novel spiral optic IOL and what the real-world trade-offs mean for patient selection.

Shortcomings of early 27-G vitrectomy systems drove the development of new technologies designed to match or surpass the performance of larger-gauge systems. The DORC TDC VELOCE represents the latest advancement - a next-generation high-speed cutter that reaches its full potential when combined with the DORC EVA NEXUS surgical system.

Jordana Fein, MD, MS, presented 64-week QUASAR data showing aflibercept 8 mg sustained visual acuity gains with up to 3 fewer injections than aflibercept 2 mg in macular edema following RVO.

When patients fall outside pivotal clinical trial criteria, retina specialists factor in real-world judgment to guide treatment.

A single vorolanib intravitreal insert extended time to supplemental anti-VEGF injection vs aflibercept in previously treated DME at 24 weeks in phase 2 VERONA; pivotal phase 3 trials COMO and CAPRI are now underway.

For Caroline R. Baumal, MD, a path from academic retina through industry leadership has brought her full circle—back to the clinic with a broader view of the field.

Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.

The phase 2 EVIAN study (Early Vitrectomy and Intravitreal Antibiotics for Post-Operative Exogenous Endophthalmitis) (NCT 04522661) showed that performing early vitrectomy for acute endophthalmitis can offer better and faster visual outcomes than the current treament of prescribing antibiotics first.

Three cases illustrate treatment switches and extension intervals across retinal vein occlusion, age-related macular degeneration, and diabetic retinopathy.

Arun C. Gulani, MD, introduces the Gulani classification of refractive lens exchange, a 4-type framework for individualizing premium IOL selection and surgical strategy around each eye's visual potential rather than its diagnosis.

Hasenin Al-khersan, MD, of the Retina Group of Florida, shares real-world RCA registry findings showing that pegcetacoplan significantly reduced both photoreceptor and RPE loss in eyes with GA.

Susvimo works in conjunction with the company’s port delivery platform, Contivue, which was specifically engineered for use with Susvimo.

Charles Wykoff, MD, PhD, of Retina Consultants of Texas, discusses 1 year of real-world revakinagene taroretcel experience, covering patient selection, surgical technique, early safety outcomes, and the platform’s potential beyond MacTel.

Physician AI use has more than doubled since 2023—but the next leap in ophthalmology won't come from smarter diagnostic algorithms alone.

Glaukos finishes US pivotal enrollment for PRESERFLO MicroShunt, targeting advanced glaucoma after failed surgeries, with 12‑month IOP reduction data guiding FDA plans.

A study of YB-101, a potential treatment for both Graves' disease and thyroid eye disease, has begun dosing the first patients. The molecule receive Fast Track Designation from the FDA.

Outlining the benefits of modulating the gut microbiome in diabetes.

Intravitreal injection of 2% hydroxypropylmethylcellulose (HPMC) dispersive viscoelastic (Eyefill HD, Bausch+Lomb) improved vision and restored ocular anatomy in eyes with structural hypotony that had visual potential.

The trial will enroll approximately 111 patients across the US and Europe following positive FDA feedback from a Type D meeting

Why AI-driven functional imaging could change how clinicians assess and treat retinal disease

The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States.

A University of Chicago-led ASRS 2026 poster explores how large language and vision-language models could help retina specialists manage imaging, records, and clinical trial matching—without replacing physician judgment.

At ASRS 2026, the dual inflammasome inhibitor K8 slowed geographic atrophy lesion growth by up to 54% over 6 months in a phase 2 trial and showed a visual acuity advantage in eyes with extrafoveal lesions, with no drug-related serious adverse events.

Louie Cai, MD, discusses why manual prescreening is so labor-intensive, how the study was designed, and what broader adoption of AI-assisted screening could mean for clinician time, patient satisfaction, and the pace of drug development.

Danon disease is a rare, multisystem X-linked genetic disorder caused by variants in the LAMP2 gene. In children and young adults, it is defined overwhelmingly by its cardiac effects . What is far less appreciated is that the eye is frequently involved and that the retinal findings can appear before the systemic diagnosis is established.